FDA Approves Zanvastro, First Targeted Treatment for Rare Alexander Disease
The U.S. Food and Drug Administration (FDA) has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients, marking the first FDA-approved therapy for this rare and progressive neurological disorder.











